April 2nd, 2020
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.
Should I buy Novartis stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Novartis stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novartis stock a buy?
Financial institutions and banks post stock ratings everyday.Unfortunately, we couldn't find any rating for NVS stock for the last 30 days.
Novartis stock analysis
Novartis shares soared 3.25% to $83.56 today.
Shares of Novartis closed today at $83.56 and soared a great 3.25%. In the last 28 days when NVS stock price broke down the SMA200d line, it slid $-4.09 per share (-4.67%). From a daily perspective, NVS is in a short term uptrend after plotting its last bottom ($70.23, on Mar/23) higher than the previous bottom, and its last top ($83.21, on March/31) also over the previous top. Now trading in between its last bottom and last top NVS might consolidate in a plain range, waiting to break out over $83.21 or down under $70.23. On February, NVS hit new all time highs, pushing higher previous ATH of $94.85 recorded on February. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Novartis boosted a phenomenal 5.40% this week. By mid March NVS collapsed a dreadful -9.93% in just one week.
Not so far away is the last all-time high Novartis marked by mid February. Since late February, when NVS stock price broke down the 40-weeks moving avarage line, it slid $-9.81 per share (-10.51%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Novartis stock price history
Novartis IPO was on November 7th, 1996 at $12.34 per share1. Since then, NVS stock grew a 577.10%, with a yearly average of 25.10%. If you had invested right after NVS's IPO a $1,000 in Novartis stock in 1996, it would worth $5,771.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Novartis stock historical price chart
NVS stock reached all-time highs on February with a price of $96.34.
Novartis stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price target for Novartis stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Novartis missed the forecasts of the experts and posted a disappointing EPS of $1.24 per share when experts were expecting $1.33.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Novartis annual sales soared a more than good 6.05% to $53,166.00 M dollars from $50,135.00 marked in 2017. However, its earnings margin (compared to revenues) rose to 23.72%, that is $12,611.00 million.
|2013||$48,290 M||-||$8,520 M17.6%||-|
|2014||$53,634 M||11.07%||$10,210 M19.0%||19.84%|
|2015||$50,387 M||-6.05%||$17,783 M35.3%||74.17%|
|2016||$49,436 M||-1.89%||$6,712 M13.6%||-62.26%|
|2017||$50,135 M||1.41%||$7,703 M15.4%||14.76%|
|2018||$53,166 M||6.05%||$12,611 M23.7%||63.72%|
Quarterly financial resultsNovartis reported $13,664.00 million in sales for 2018-Q4, a 4.14% up compared to previous quarter. Reported quarter income marked $1,195.00 M with a profit margin of 8.75%. Profit margin decreased a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing revenues to same quarter last year, Novartis sales marked a beatiful gain and raised a 3.80%.
|2017-Q2||$12,050 M||-||$1,950 M16.2%||-|
|2017-Q3||$11,950 M||-0.83%||$2,000 M16.7%||2.56%|
|2017-Q4||$13,164 M||10.16%||$1,976 M15.0%||-1.20%|
|2018-Q1||$12,929 M||-1.79%||$2,025 M15.7%||2.48%|
|2018-Q2||$13,452 M||4.05%||$7,768 M57.7%||283.60%|
|2018-Q3||$13,121 M||-2.46%||$1,623 M12.4%||-79.11%|
|2018-Q4||$13,664 M||4.14%||$1,195 M8.7%||-26.37%|
|2019-Q1||$11,455 M||-16.17%||$1,766 M15.4%||47.78%|
Novartis ownershipWhen you are planning to invest in shares of a stock, it's worth to review its ownership structure.
Novartis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Novartis stock, 11.31% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$189.7 B|
|Total shares||2,270.0 M|
|Float shares||2,120.0 M|
|- Institutional holdings (%)||11.3%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, April 2nd, 2020|
|Day range||$81.49 - $83.62|
|Average true range||$4.13|
|50d mov avg||$85.61|
|100d mov avg||$87.60|
|200d mov avg||$86.78|
Novartis performanceTo better understand Novartis performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Novartis to :
Novartis competitorsUnfortunately, we could not find any public company that could be defined as Novartis competitor. This doesn't mean Novartis does not have any competitor in the market, it's just we could not detected it.
Latest Novartis stock news
- Seeking AlphaNovartis' Accelerated Review Sets Up A Potential Catalyst For FDA ApprovalJuly 25, 2019
- Seeking AlphaNovartis: A Transformation Story Not To Miss In 2019June 28, 2019
- Seeking AlphaNovartis Makes Substantial Pipeline Progress On A Couple Of FrontsJune 13, 2019
- Seeking AlphaNovartis Kisqali Might Have A Path Forward To Take On Pfizer's IbranceJune 11, 2019
- Seeking AlphaNovartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In DevelopmentJune 4, 2019